CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Oral sildenafil 20 mgdrug
Likely dose
Oral sildenafil 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01948518
NCT01948518N/ACompleted
CompareCT.gov

The Effect of Sildenafil on Diffusion Capacity Measurements in Patients With Pulmonary Hypertension and Parenchymal Lung Disease

The Cleveland Clinic·interventional·Posted Sep 23, 2013·Updated Sep 30, 2014

In Brief

A clinical study evaluating Oral sildenafil 20 mg for Diffuse Parenchymal Lung Disease and Pulmonary Hypertension. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study was to investigate the acute effects of sildenafil on diffusion capacity, a commonly performed pulmonary function test, which is used to assess the lungs' gas exchange capability. This study does not assess safety or efficacy of the drug. The study does not have clinical end points. The variables studied are diffusion capacity and 6 minute walk after a single dose of sildenafil. This study has been completed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Parenchymal Lung Disease, Pulmonary Hypertension
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 23, 2013
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 12.8 years ago

Interventions

Oral sildenafil 20 mgdrug

A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.